{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T19:03:29Z","timestamp":1788462209478,"version":"build-2803163510"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T00:00:00Z","timestamp":1600041600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T00:00:00Z","timestamp":1600041600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin Experimental Derm"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1111\/ced.14412","type":"journal-article","created":{"date-parts":[[2020,8,8]],"date-time":"2020-08-08T00:23:16Z","timestamp":1596846196000},"page":"122-129","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["A phase I, randomized, double\u2010blind study to assess the safety, tolerability and efficacy of the topical RORC2 inverse agonist PF\u201006763809 in participants with mild\u2010to\u2010moderate plaque psoriasis"],"prefix":"10.1093","volume":"46","author":[{"given":"G.","family":"Berstein","sequence":"first","affiliation":[{"name":"Inflammation and Immunology Research Unit Pfizer Inc. Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Zhang","sequence":"additional","affiliation":[{"name":"Inflammation and Immunology Research Unit Pfizer Inc. Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Berger","sequence":"additional","affiliation":[{"name":"Inflammation and Immunology Research Unit Pfizer Inc. Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Kieras","sequence":"additional","affiliation":[{"name":"Inflammation and Immunology Research Unit Pfizer Inc. Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Li","sequence":"additional","affiliation":[{"name":"Early Clinical Development Pfizer Inc., Collegeville PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Samuel","sequence":"additional","affiliation":[{"name":"Formulation and Process Design Pfizer Inc. Groton CT USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Yeoh","sequence":"additional","affiliation":[{"name":"Formulation and Process Design Pfizer Inc. Groton CT USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Dowty","sequence":"additional","affiliation":[{"name":"Inflammation and Immunology Research Unit Pfizer Inc. Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Beaumont","sequence":"additional","affiliation":[{"name":"Inflammation and Immunology Research Unit Pfizer Inc. Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Wigger\u2010Alberti","sequence":"additional","affiliation":[{"name":"Bioskin GmbH Hamburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"von Mackensen","sequence":"additional","affiliation":[{"name":"Bioskin GmbH Hamburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Kroencke","sequence":"additional","affiliation":[{"name":"Bioskin GmbH Hamburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Hamscho","sequence":"additional","affiliation":[{"name":"Rothhaar Studien GmbH Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Garcet","sequence":"additional","affiliation":[{"name":"Rockefeller University New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. G.","family":"Krueger","sequence":"additional","affiliation":[{"name":"Rockefeller University New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Banfield","sequence":"additional","affiliation":[{"name":"Inflammation and Immunology Research Unit Pfizer Inc. Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Oemar","sequence":"additional","affiliation":[{"name":"Inflammation and Immunology Research Unit Pfizer Inc. Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,9,14]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-010-1080-1"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546630600920041"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa4282"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2006.07.035"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2014.09.002"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-018-8702-3"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5701213"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.7.4733"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314258"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512711"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503824"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.03.037"},{"key":"e_1_2_9_14_1","first-page":"1 (poster 001)","article-title":"First evidence of efficacy of an orally active ROR\u03b3t inhibitor in the treatment of patients with moderate to severe plaque psoriasis","volume":"25","author":"Palmer S","year":"2016","journal-title":"Exp Dermatol"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1996.03890300076011"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1159\/000458415"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1046"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2019.11.027"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1018961511730"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00216-018-0964-3"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1159\/000313514"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1159\/000056386"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425247.2013.776038"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16131"},{"key":"e_1_2_9_25_1","unstructured":"Warner Chilcott (US) I.Dovonex (calcipotriene solution) scalp solution 0.005%.2007. Available athttps:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/020611s007 020554s007 020273s009lbl.pdf(accessed7 February 2020)."},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12514266"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fced.14412","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ced.14412","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ced.14412","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ced.14412","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T14:53:07Z","timestamp":1676386387000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/46\/1\/122\/6598356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,14]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["10.1111\/ced.14412"],"URL":"https:\/\/doi.org\/10.1111\/ced.14412","archive":["Portico"],"relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,14]]},"assertion":[{"value":"2020-06-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}